2024 (1 POST)
Mathisen GH, Bearth A, Jones LB, Hoffmann S, Vist GE, Ames HM,… Wikoff D , Wright F, Whaley P. 2024. Editorial: Time for CHANGE: System-level interventions for bringing forward the date of effective use of NAMs in regulatory toxicology. Arch Toxicol 98(8):2299-2308; doi: 10.1007/s00204-024-03802-6 . PMID: 38877155.
View Abstract
Publication: Manuscripts
2023 (1 POST)
Thompson CM , Proctor DM , Harris MA. 2023. Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data.” Environ Mol Mutagen 64(4):259–260; doi: 10.1002/em.22537 . PMID: 36916184.
Publication: Manuscripts
2019 (3 POSTS)
Thompson CM . The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, August 2019.
Publication: Abstracts and Presentations
Proctor D . Use of the latest science in cancer risk assessment for hexavalent chromium: Is it time to step away from the default regulatory approaches? Invited presentation to the International Union of Toxicology (IUTOX) / International Congress of Toxicology (ICT) meeting, Honolulu, HI, June 2019.
Publication: Abstracts and Presentations
Choksi NY , Truax J, Layton A, Matheson J, Mattie D, Varney T, et al. 2019. United States regulatory requirements for skin and eye irritation testing. Cutan Ocul Toxicol 38(2):141–155; doi: 10.1080/15569527.2018.1540494 .
View Abstract
Publication: Manuscripts
2018 (3 POSTS)
Wikoff D . Moving beyond theory to the use of systematic review to support regulatory decision making for evidence-based risk assessment. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.
View Abstract
Publication: Abstracts and Presentations
Proctor DM . Updating the regulatory risk assessment for hexavalent chromium in California: Implications for regulatory standards. Association of Environmental Health Sciences San Diego, CA, March 2018.
Publication: Abstracts and Presentations
Drechsel DA, Barlow CA, Bare JL , Jacobs NF, Henshaw JL. 2018. Historical evolution of regulatory standards for occupational and consumer exposures to industrial talc. Regul Toxicol Pharmacol 92(Feb):251–267; doi: 10.1016/j.yrtph.2017.12.005 .
View Abstract
Publication: Manuscripts
2017 (1 POST)
Vincent MJ , Bernstein JA, Basketter D, LaKind JS, Dotson GS, Maier A. 2017. Chemical-induced asthma and the role of clinical, toxicological, exposure and epidemiological research in regulatory and hazard characterization approaches. Regul Toxicol Pharmacol 90(Nov):126–132; doi: 10.1016/j.yrtph.2017.08.018 .
View Abstract
Publication: Manuscripts
2016 (1 POST)
Ulrich K . Adversity and risk assessment of respiratory tract findings — A regulatory perspective. Presentation to the 31st Annual Meeting of the British Society of Toxicological Pathology (BSTP) — Association of Inhalation Toxicologists Joint Conference, Alderley Edge, Cheshire, UK, 2016.
Publication: Abstracts and Presentations
2015 (1 POST)
Reddick H . An introduction to regulatory toxicology. Science Teachers and Industry Workshop, Kilgore, TX, 2015.
Publication: Abstracts and Presentations
2011 (1 POST)
Sistare FD, Morton D, Alden C, Christensen J, Keller D , Jonghe SD, et al. 2011. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: Support for a proposal to modify current regulatory guidelines. Toxicol Pathol 39(4):716–744; doi: 10.1177/0192623311406935 .
View Abstract
Publication: Manuscripts
1996 (1 POST)
Sauers L and Perry C . 1996. Regulatory affairs – A growing opportunity for toxicologists. SOT Communiqué, May/June 1996.